Probiotic Formulation VSL#3 Interacts with Mesenchymal Stromal Cells To Protect Dopaminergic Neurons via Centrally and Peripherally Suppressing NOD-Like Receptor Protein 3 Inflammasome-Mediated Inflammation in Parkinson's Disease Mice.
NLRP3 inflammasome
Parkinson’s disease
anti-inflammatory
mesenchymal stromal cells
probiotic
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
02 Feb 2023
02 Feb 2023
Historique:
entrez:
2
2
2023
pubmed:
3
2
2023
medline:
3
2
2023
Statut:
aheadofprint
Résumé
Systemic immunomodulation is increasingly recognized among the beneficial effects of mesenchymal stromal cells (MSCs) in treatment of Parkinson's disease (PD), while the underlying mechanism is not fully understood. With the growing popularity of using probiotics as an adjuvant approach in PD treatment, concerns about the added effects of probiotics have been raised. In addition to the molecular mechanism mediating the neuroprotective effects of MSCs, the combined effects of a probiotic formulation, VSL#3, and MSC infusion were also evaluated in PD mice. The animals were weekly treated with human MSCs (hMSCs) via the tail vein, VSL#3 via the gastrointestinal tract, or their combination six times. hMSCs, VSL#3 alone, and their combination markedly ameliorated the decreased striatal dopamine content, loss of dopaminergic neurons in the substantia nigra, increased levels of proinflammatory cytokines in serum, as well as tumor necrosis factor alpha (TNF-α) and interleukin-1β (IL-1β) mRNAs in striatum and peripheral tissues induced by MPTP. Furthermore, hMSCs, VSL#3, and their combination notably downregulated mRNA expression of NOD-like receptor protein 3 (NLRP3) and caspase-1 in brain and peripheral tissues of PD mice. These results suggest that hMSCs, VSL#3, and their combination prevent neurodegenerative changes in PD mice via anti-inflammatory activities in both the central and peripheral systems, possibly through suppressing the NLRP3 inflammasome. Moreover, two-way analysis of variance (ANOVA) indicated that VSL#3 interacts with hMSCs to attenuate neurodegeneration and inhibit NLRP3 inflammasome-mediated inflammation without altering the effects of hMSCs. Major findings of our study support the usage of probiotic formulation VSL#3 as an adjuvant therapy to hMSC infusion in PD treatment.
Identifiants
pubmed: 36728426
doi: 10.1128/spectrum.03208-22
pmc: PMC10100967
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0320822Références
Curr Top Med Chem. 2015;15(21):2193-210
pubmed: 26059357
Stem Cell Res Ther. 2021 May 17;12(1):290
pubmed: 34001255
Cell. 2010 Mar 19;140(6):821-32
pubmed: 20303873
Int J Mol Sci. 2019 Aug 23;20(17):
pubmed: 31450864
Nat Rev Drug Discov. 2019 Jun;18(6):405-407
pubmed: 31160775
Cell Mol Life Sci. 2020 Jul;77(14):2771-2794
pubmed: 31965214
Am J Physiol Endocrinol Metab. 2016 Feb 1;310(3):E183-9
pubmed: 26646097
Cytotherapy. 2016 Mar;18(3):307-19
pubmed: 26857226
World J Stem Cells. 2021 Dec 26;13(12):1905-1917
pubmed: 35069989
Cytotherapy. 2010 Apr;12(2):260-4
pubmed: 19929457
Circulation. 2005 Sep 6;112(10):1451-61
pubmed: 16129797
Cell Death Differ. 2019 Jan;26(2):213-228
pubmed: 29786072
Stem Cells. 2014 Jun;32(6):1553-63
pubmed: 24307525
Naunyn Schmiedebergs Arch Pharmacol. 2020 Feb;393(2):147-165
pubmed: 31468077
PLoS One. 2012;7(9):e45757
pubmed: 23049854
Biomed Pharmacother. 2022 Sep;153:113535
pubmed: 36076517
J Neurol Neurosurg Psychiatry. 2006 Dec;77(12):1323-8
pubmed: 16952917
Parkinsons Dis. 2011 Feb 22;2011:436813
pubmed: 21403862
J Cell Mol Med. 2019 Aug;23(8):5466-5474
pubmed: 31148353
Front Cell Dev Biol. 2022 Jan 20;9:808905
pubmed: 35127723
J Neuroinflammation. 2021 Jan 9;18(1):20
pubmed: 33422110
J Neuroimmunol. 2021 May 15;354:577543
pubmed: 33714750
Int J Mol Sci. 2020 Oct 30;21(21):
pubmed: 33143234
Curr Top Behav Neurosci. 2015;22:205-20
pubmed: 24850081
J Neuroinflammation. 2019 Apr 10;16(1):78
pubmed: 30971286
J Nutr. 2015 Jun;145(6):1354-61
pubmed: 25948785
Biomed Pharmacother. 2021 Oct;142:111971
pubmed: 34343893
Neurobiol Dis. 2020 Oct;144:105028
pubmed: 32736085
Neuropathol Appl Neurobiol. 2021 Feb;47(1):43-60
pubmed: 32696999
Dev Comp Immunol. 2019 Mar;92:77-86
pubmed: 30227219
Mol Neurobiol. 2021 Apr;58(4):1303-1311
pubmed: 33169332
Front Endocrinol (Lausanne). 2022 Feb 24;13:817146
pubmed: 35282447
Curr Opin Neurol. 2013 Aug;26(4):374-80
pubmed: 23817213
Neurochem Res. 2018 Oct;43(10):1986-1999
pubmed: 30171422
Biochim Biophys Acta. 2012 Feb;1822(2):176-84
pubmed: 22119596
Stem Cell Res Ther. 2017 Apr 18;8(1):85
pubmed: 28420415
J Neuroinflammation. 2018 Jul 2;15(1):193
pubmed: 29966531
J Neurochem. 2016 Oct;139 Suppl 1:156-178
pubmed: 26865375
NPJ Parkinsons Dis. 2018 Aug 15;4:24
pubmed: 30131971
Front Cell Neurosci. 2018 Nov 06;12:398
pubmed: 30459561